CN105189544A - 具有抗肿瘤活性的新颖的双特异性结合分子 - Google Patents

具有抗肿瘤活性的新颖的双特异性结合分子 Download PDF

Info

Publication number
CN105189544A
CN105189544A CN201480022196.2A CN201480022196A CN105189544A CN 105189544 A CN105189544 A CN 105189544A CN 201480022196 A CN201480022196 A CN 201480022196A CN 105189544 A CN105189544 A CN 105189544A
Authority
CN
China
Prior art keywords
seq
antibody
cells
polypeptide
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480022196.2A
Other languages
English (en)
Chinese (zh)
Inventor
F·布勒
U·维尔纳
K·克卢普施
I·斯宾登
R·桑迪玛利亚
I·阿廷杰-托勒
S·柯尼希-弗里德里克
J·贝尔采钦格曼
D·格拉布洛夫斯基
S·布拉克
M·西拉奇
R·伍兹
H·哈希米
P·埃纳
U·冯德贝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cilag GmbH International
Original Assignee
Covagen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covagen AG filed Critical Covagen AG
Publication of CN105189544A publication Critical patent/CN105189544A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
CN201480022196.2A 2013-04-19 2014-03-06 具有抗肿瘤活性的新颖的双特异性结合分子 Pending CN105189544A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13164555 2013-04-19
EP13164555.8 2013-04-19
PCT/EP2014/054390 WO2014170063A1 (en) 2013-04-19 2014-03-06 Novel bispecific binding molecules with antitumoral activity

Publications (1)

Publication Number Publication Date
CN105189544A true CN105189544A (zh) 2015-12-23

Family

ID=48128216

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480022196.2A Pending CN105189544A (zh) 2013-04-19 2014-03-06 具有抗肿瘤活性的新颖的双特异性结合分子

Country Status (15)

Country Link
EP (1) EP2986630B1 (enExample)
JP (2) JP6694808B2 (enExample)
KR (1) KR20160002882A (enExample)
CN (1) CN105189544A (enExample)
AU (1) AU2014256037B2 (enExample)
BR (1) BR112015026143A2 (enExample)
CA (1) CA2908988A1 (enExample)
CL (1) CL2015003085A1 (enExample)
EA (1) EA201592006A1 (enExample)
HK (1) HK1214605A1 (enExample)
MX (1) MX2015014608A (enExample)
PH (1) PH12015502278A1 (enExample)
SG (1) SG11201508231UA (enExample)
WO (1) WO2014170063A1 (enExample)
ZA (1) ZA201507752B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110536904A (zh) * 2017-04-03 2019-12-03 科瓦根股份公司 Fgfr3结合分子
CN111315773A (zh) * 2017-09-08 2020-06-19 马弗里克治疗公司 含有Fc区的条件性活化的结合部分
US11744892B2 (en) 2017-09-08 2023-09-05 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
ES2984771T3 (es) 2012-06-13 2024-10-31 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
CN112390883A (zh) 2013-12-17 2021-02-23 基因泰克公司 抗cd3抗体及使用方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EA038045B1 (ru) 2015-02-20 2021-06-28 Инсайт Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016204966A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
FI126633B (en) 2015-07-10 2017-03-15 Next Biomed Therapies Oy Method for the preparation of a library of derivatives of the SH3 domain of recombinant nephrocystin (NPHP1)
KR20190074300A (ko) 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
MX2019012606A (es) * 2017-04-24 2019-12-02 Ichnos Sciences SA Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr.
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019033050A1 (en) * 2017-08-11 2019-02-14 City Of Hope BISPECIFIC MOLECULE FOR BINDING TO ANTIGEN
AU2018314236B2 (en) 2017-08-11 2025-02-06 Apterna Limited RNA aptamers against transferrin receptor (TfR)
US20190153096A1 (en) 2017-10-02 2019-05-23 Covagen Ag Cd3/cd33 bispecific binding molecules
US20190100587A1 (en) * 2017-10-02 2019-04-04 Covagen Ag IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
CA3089287A1 (en) 2018-02-08 2019-08-15 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
PH12022550892A1 (en) 2019-10-14 2023-05-03 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3164226A1 (en) 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
AR120741A1 (es) 2019-12-13 2022-03-16 Genentech Inc Anticuerpos anti-ly6g6d y métodos de uso
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
IL302396A (en) 2020-11-04 2023-06-01 Genentech Inc Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies
JP7716473B2 (ja) 2020-11-04 2025-07-31 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
AU2022273541A1 (en) 2021-05-14 2023-11-30 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US20250223376A1 (en) 2021-09-20 2025-07-10 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
AR129061A1 (es) 2022-04-13 2024-07-10 Genentech Inc Composiciones farmacéuticas de mosunetuzumab y métodos de uso
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025221728A2 (en) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Ltbr binding molecules and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011023685A1 (en) * 2009-08-27 2011-03-03 Covagen Ag Il-17 binding compounds and medical uses thereof
WO2011116387A1 (en) * 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
WO2011147986A1 (en) * 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011023685A1 (en) * 2009-08-27 2011-03-03 Covagen Ag Il-17 binding compounds and medical uses thereof
WO2011116387A1 (en) * 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GRABULOVSKI D等: "A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties", 《JOURNAL OF BIOLOGICAL CHEMISTRY》 *
HUI REN等: "Anti-HER-2xanti-CD3 Bi-specific Antibodies inhibit growth of HCT-116 colorectal carcinoma cells in vitro and in vivo", 《ASIAN PACIFIC JOURNAL OF CANCER PREVENTION》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
CN110536904A (zh) * 2017-04-03 2019-12-03 科瓦根股份公司 Fgfr3结合分子
CN111315773A (zh) * 2017-09-08 2020-06-19 马弗里克治疗公司 含有Fc区的条件性活化的结合部分
US11744892B2 (en) 2017-09-08 2023-09-05 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
US11744893B2 (en) 2017-09-08 2023-09-05 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
US12478673B2 (en) 2017-09-08 2025-11-25 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins

Also Published As

Publication number Publication date
JP2016516789A (ja) 2016-06-09
KR20160002882A (ko) 2016-01-08
JP2019106997A (ja) 2019-07-04
HK1214605A1 (zh) 2016-07-29
JP6694808B2 (ja) 2020-05-20
EP2986630A1 (en) 2016-02-24
AU2014256037B2 (en) 2017-09-21
MX2015014608A (es) 2016-03-03
PH12015502278A1 (en) 2016-02-01
EP2986630B1 (en) 2018-08-15
SG11201508231UA (en) 2015-11-27
CA2908988A1 (en) 2014-10-23
EA201592006A1 (ru) 2016-03-31
BR112015026143A2 (pt) 2017-10-17
ZA201507752B (en) 2017-03-29
WO2014170063A1 (en) 2014-10-23
CL2015003085A1 (es) 2016-06-03
AU2014256037A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
EP2986630B1 (en) Novel bispecific binding molecules with antitumoral activity
EP3820569B1 (en) Antibody molecules that bind pd-l1 and cd137
EP3443000B1 (en) Cd80 variant immunomodulatory proteins and uses thereof
RU2693661C2 (ru) Антитело против pdl-1, его фармацевтическая композиция и применение
CN113301919B (zh) 激活免疫细胞的双特异性抗体
JP7418346B2 (ja) ４－１ＢＢＬを含むＨｅｒ２標的化抗原結合分子
KR102505383B1 (ko) Dll3 표적 다중 특이성 항원 결합 분자 및 그의 사용
EP3331902B1 (en) Constructs having a sirp-alpha domain or variant thereof
KR20230029621A (ko) T 세포 억제 단백질을 포함하거나 포함하지 않는 april 및 baff 억제 면역조절 단백질 및 이의 사용 방법
TW202227503A (zh) 改良之抗原結合受體
CA3117853A1 (en) Novel rationally designed protein compositions
TW202221021A (zh) 改良之抗原結合受體
CN113227142B (zh) 抗pd-1抗体及其用途
US12240901B2 (en) Humanized anti-BASIGIN antibodies and the use thereof
AU2022297538A1 (en) Extended-release immune cell engaging proteins and methods of treatment
CN120322461A (zh) 新型抗gprc5d抗体
WO2025061050A9 (en) Antibodies targeting ctla4 and cd47 and uses thereof
CN120826234A (zh) 抗EGFRvIII/抗CD3抗体与肿瘤靶向性4-1BB激动剂的组合疗法
KR20130057959A (ko) 항 ｈｅｒ2 단일클론항체와 ｉｌ-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물
KR20140025836A (ko) 항 ＨＥＲ2/Ｎｅｕ 단일클론항체와 ＩＬ-7가 연결된 융합 단일클론 항체 및 이를 포함하는 암 치료용 조성물
RU2826084C2 (ru) МОЛЕКУЛЫ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ PD-L1 и CD137
HK40050345B (en) Antibody molecules that bind pd-l1 and cd137
HK40050345A (en) Antibody molecules that bind pd-l1 and cd137

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151223